Alkermes Plc (ALKS) Releases Earnings Results, Beats Expectations By $0.09 EPS

Alkermes Plc (ALKS) reported quarterly earnings results on Thursday, Jul-28-2016. The company said it had a profit of $-0.01 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.09. Analysts had a consensus of $-0.10. The company posted revenue of $195.20 million in the period, compared to analysts expectations of $174.17 million. The company’s revenue was up 28.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.09 EPS.

Alkermes Plc closed down -3.65 points or -7.05% at $48.13 with 17,12,934 shares getting traded on Thursday. Post opening the session at $51.07, the shares hit an intraday low of $47.23 and an intraday high of $51.5 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

In a different news, on Jul 6, 2016, Paul J Mitchell (director) sold 2,000 shares at $45.81 per share price. According to the SEC, on Apr 20, 2016, Richard F Pops (Director and CEO, Alkermes plc) sold 18,750 shares at $40.15 per share price. On Apr 20, 2016, Michael J Landine (SVP, Corp Dev., Alkermes, Inc.) sold 16,875 shares at $41.12 per share price, according to the Form-4 filing with the securities and exchange commission.

Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching developing and commercializing both with partners and on its own pharmaceutical products that are designed to meet unmet medical needs of patients in major therapeutic areas. The Company has a portfolio of more than 20 products and a clinical pipeline of product candidates being developed for the treatment of central nervous system (CNS) disorders such as addiction schizophrenia and depression. The Company is conducting clinical studies on new pharmaceutical products. These include Aripiprazole Lauroxil ALKS 5461 ALKS 3831 ALKS 8700 and RDB 1419. The Company’s main marketed products include RISPERDAL CONSTA INVEGA SUSTENNA/XEPLION AMPYRA/FAMPYRA BYDUREON and VIVITROL.

Alkermes Plc

Leave a Reply

Alkermes Plc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Alkermes Plc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.